Published in Clinical Oncology Week, April 4th, 2005
According to a study from Italy, "Plasmid DNA vectors encoding the full-length (VR1012/HER-2-FL) or only the extracellular and transmembrane domains (VR1012/HER-2-ECD-TM) of human (h) HER-2/neu protooncogene were used to vaccinate HER-2/neu transgenic mice (N202) engineered to overexpress the rat (r) neu protooncogene product (r-p185neu). Both the full-length and the deleted vaccines were significantly (p=0.0001 and p=0.06, respectively) more active than the empty-vector (VR1012/EV) in preventing and delaying HER-2/neu-driven...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.